[Repaglinide (NN-623)].
Kaku
K
K
Development Division, Novo Nordisk Pharma Ltd.
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002219:Carbamates / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000378:metabolism; D010880:Piperidines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011498:Protein Precursors / Q000378:metabolism
D001786:Blood Glucose; D002219:Carbamates; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; D011498:Protein Precursors; C040839:pre-hemoglobin A, glycosylated; C072379:repaglinide